Phaseline

Companies › Corium Innovations

Corium Innovations: clinical trials, targets and expected readouts

2 active drug programs in 33 registered trials: 20 Phase 4, 6 Phase 2, 5 Phase 1, 2 Phase 3; Psychiatry, Gastroenterology, Genitourinary, Infectious disease; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Estradiol
Estrogen receptor alpha agonist
ESR1Phase 1Healthy Female Participants; Menopause; Perimenopause; Infertilities …May 2027
Selegiline
Monoamine oxidase B inhibitor
MAOBPhase 1Major Depressive Disorder (MDD)–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04043520EstradiolPhase 4MenopauseMetabolic and endocrineAug 2024
NCT04255160EstradiolPhase 4PerimenopauseGenitourinarySep 2026
NCT07452692SelegilinePhase 1Major Depressive Disorder (MDD)PsychiatrySep 2026
NCT07851649EstradiolPhase 1Healthy Female ParticipantsGenitourinarySep 2026
NCT06896617EstradiolPhase 4InfertilitiesGenitourinaryNov 2026
NCT06798571EstradiolPhase 4MenopauseGenitourinaryDec 2026
NCT06969326EstradiolPhase 3Postoperative BleedingPsychiatryDec 2026
NCT07083635EstradiolPhase 2Menstruation DisturbancesGenitourinaryDec 2026
NCT05221021EstradiolPhase 4Overactive Bladder SyndromeGenitourinaryDec 2026
NCT05457972EstradiolPhase 4BreastfeedingPsychiatryDec 2026
NCT05282277EstradiolPhase 4DepressionPsychiatryDec 2026
NCT07160504EstradiolPhase 4Vagina AtrophyGenitourinaryDec 2026
NCT06570460EstradiolPhase 4Turner SyndromeMetabolic and endocrineDec 2026
NCT06570460EstradiolPhase 4Turner SyndromeMetabolic and endocrineDec 2026
NCT06544473EstradiolPhase 4Turner SyndromeMetabolic and endocrineDec 2026
NCT06544473EstradiolPhase 4Turner SyndromeMetabolic and endocrineDec 2026
NCT04685148EstradiolPhase 1Major Depressive DisorderPsychiatryDec 2026
NCT05723601EstradiolPhase 4Recurrent Urinary Tract InfectionInfectious diseaseJan 2027
NCT05723601EstradiolPhase 4Recurrent Urinary Tract InfectionInfectious diseaseJan 2027
NCT05716516EstradiolPhase 2Metastatic Breast CancerOncologyMay 2027
NCT07794150EstradiolPhase 1MenopauseGenitourinaryMay 2027
NCT06353269EstradiolPhase 4Recurrent Urinary Tract InfectionInfectious diseaseJun 2027
NCT04833140EstradiolPhase 3NASH - Nonalcoholic SteatohepatitisGastroenterologyJul 2027
NCT06856174EstradiolPhase 4HIV InfectionInfectious diseaseSep 2027
NCT07754630EstradiolPhase 2MenopauseGenitourinaryOct 2027
NCT06686537EstradiolPhase 2Infertility, FemaleMetabolic and endocrineOct 2027
NCT05900895EstradiolPhase 1Metastatic Breast CancerOncologyDec 2027
NCT06264882EstradiolPhase 4MenopauseMetabolic and endocrineMay 2028
NCT06610305EstradiolPhase 4Major Depressive DisorderPsychiatryJun 2028
NCT02238808EstradiolPhase 2Estrogen Receptor Positive Breast CancerOncologyJun 2028
NCT07831499EstradiolPhase 4MenopauseGenitourinaryJul 2028
NCT07831499EstradiolPhase 4MenopauseGenitourinaryJul 2028
NCT03875378EstradiolPhase 2Anorexia NervosaPsychiatryAug 2028

From the company's SEC filings

Complete response letters from FDA

Private offerings reported to the SEC (Form D)

Targets

ESR1 (1) MAOB (1)

Companies with the same targets

Pfizer AstraZeneca Roche Eurofarma Laboratorios Eli Lilly Shanghai Best-Link Bioscience Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair Stemline Therapeutics Atossa Therapeutics GE Healthcare

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.